Page 33 - Molecular features of low-grade developmental brain tumours

GENERAL INTRODUCTION & OUTLINE OF THE THESIS
164. Wang, Y. et al. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. Ann Neurol 61, 139-152, doi:10.1002/ana.21058 (2007).
165. Madhavan, D. et al. Surgical outcome in tuberous sclerosis complex: a multicenter survey. Epilepsia
48, 1625-1628, doi:10.1111/j.1528-1167.2007.01112.x (2007).
166. Krueger, D. A., Northrup, H. & International Tuberous Sclerosis Complex Consensus, G. Tuberous
sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49, 255-265, doi:10.1016/j. pediatrneurol.2013.08.002 (2013).
167. Holanda, F. J. & Holanda, G. M. Tuberous sclerosis - neurosurgical indications in intraventricular tumors. Neurosurg Rev 3, 139-150, doi:10.1007/BF01644066 (1980).
168. de Ribaupierre, S. et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery 60, 83-89; discussion 89-90, doi:10.1227/01. NEU.0000249216.19591.5D (2007).
169. Cai, R. & Di, X. Combined intra- and extra-endoscopic techniques for aggressive resection of subependymal giant cell astrocytomas. World Neurosurg 73, 713-718, doi:10.1016/j. wneu.2010.02.068 (2010).
170. Roszkowski, M., Drabik, K., Barszcz, S. & Jozwiak, S. Surgical treatment of intraventricular tumors associated with tuberous sclerosis. Childs Nerv Syst 11, 335-339, doi:10.1007/BF00301665 (1995).
171. Pascual-Castroviejo, I. Neurosurgical treatment of tuberous sclerosis complex lesions. Childs Nerv Syst 27, 1211-1219, doi:10.1007/s00381-011-1488-8 (2011).
172. Rodgers, S. D., Bassani, L., Weiner, H. L. & Harter, D. H. Stereotactic endoscopic resection and surgical management of a subependymal giant cell astrocytoma: case report. J Neurosurg Pediatr 9, 417-420, doi:10.3171/2011.12.PEDS11349 (2012).
173. Nishio, S. et al. Subependymal giant cell astrocytoma: clinical and neuroimaging features of four cases. J Clin Neurosci 8, 31-34, doi:10.1054/jocn.2000.0767 (2001).
174. Kotulska, K. et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol 50, 307-312, doi:10.1016/j.pediatrneurol.2013.12.004 (2014).
175. Giordano, F. et al. Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous
sclerosis complex: a series of 44 surgical procedures in 31 patients. Childs Nerv Syst 36, 951-960,
doi:10.1007/s00381-019-04449-w (2020).
176. Arroyo, M. S., Krueger, D. A., Broomall, E., Stevenson, C. B. & Franz, D. N. Acute Management of
Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. Pediatr Neurol 72, 81-85,
doi:10.1016/j.pediatrneurol.2017.04.008 (2017).
177. Moavero, R. et al. Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell
Astrocytomas. Pediatr Neurol 68, 59-63, doi:10.1016/j.pediatrneurol.2016.11.003 (2017).
178. Lam, C. et al. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous
system tumors. Pediatr Blood Cancer 54, 476-479, doi:10.1002/pbc.22298 (2010).
179. Cardamone, M. et al. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr 164, 1195-1200,
doi:10.1016/j.jpeds.2013.12.053 (2014).
180.Koenig, M. K., Butler, I. J. & Northrup, H. Regression of subependymal giant cell
astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 23, 1238-1239,
doi:10.1177/0883073808321764 (2008).
181. Franz, D. N. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas
associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-
31
1